Asubio Broadens Inclusion Criteria For Landmark Spinal Cord Injury Clinical Trial

http://online.wsj.com/article/PR-CO-20130708-904357.html

Asubio Pharmaceuticals, Inc. today announced the expansion of enrollment for its ASCENT-ASCI (Asubio Spinal Cord Early Neuro-recovery Treatment for Acute Spinal Cord Injury) trial to include AIS A, B and C injury to the cervical spine. ASCENT-ASCI is a Phase 2 clinical trial evaluating SUN13837…